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ABSTRACT
Kisspeptins – Expression, Purification, and Biological Assays
by
Mathew P. Kurian, Doctor of Philosophy
Utah State University, 2013
Major Professor: Randolph V. Lewis
Department: Biology
Kisspeptins are an arginine-phenylalanine-amide family of neuroactive peptide
hormones encoded by the KISS1 gene, which, along with its receptor GPR54, are
essential for the initiation of puberty in adolescents and maintenance of reproductive
function in adults. Kisspeptins are also involved in the sexual dimorphism of the brain.
Kisspeptin signaling defects are implicated in reproductive disorders like idiopathic
hypogonadotropic hypogonadism, precocious puberty and polycystic ovarian syndrome.
Kisspeptins were originally discovered as metastasis suppressors in melanoma cell lines
and have also been found to down regulate metastasis in breast and ovarian cancers. They
have been found to inhibit the colonization of secondary tissues by the metastatic cancer
cells. Kisspeptins also relay nutritional status to the reproductive system. However, little
is known about the mechanism of action of kisspeptins in a cellular and biochemical
context. Therefore, an important goal is the synthesis of kisspeptins in sufficient
quantities for use as experimental and therapeutic reagents.
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In this study, we developed a simple and cost-effective method to express and
purify kisspeptins in large quantities. We designed the kisspeptin constructs in-silico and
expressed them in an Escherichia coli bacterial system. The purification was then
optimized using standard chromatographic techniques. In anticipation of future demands,
we successfully scaled the expression and purification of the kisspeptins using larger
bioreactors and chromatography systems. We tested the biological activity of the
kisspeptin we produced on mammalian cell lines expressing the kisspeptin receptor and
compared its actions to the kisspeptins synthesized by chemical means. We found that
kisspeptins activated two proteins involved in the cell proliferation underlying metastasis.
Thus, we were able to show that the much lower cost kisspeptins synthesized by
Escherichia coli act similarly to proteins manufactured by chemical synthesis.

(100 pages)
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PUBLIC ABSTRACT
Kisspeptins – Expression, Purification, and Biological Assays
by
Mathew P. Kurian, Doctor of Philosophy
Utah State University, 2013
Major Professor: Randolph V. Lewis
Department: Biology
Kisspeptins are hormones involved in the onset of puberty in adolescents and
maintenance of reproductive function in adults. Defects in kisspeptin signaling are
associated with many reproductive disorders. Kisspeptins were originally discovered as
metastasis suppressors and have been found to suppress the metastasis of certain cancers.
Unfortunately, many aspects of kisspeptin action at a cellular level remain unknown.
Kisspeptins, therefore, are attractive candidates for large-scale production for use as
research and therapeutic reagents. We developed a simple and cost effective method to
express and purify kisspeptins in large quantities. We also tested the biological activity of
kisspeptins on cells expressing receptors for kisspeptins and found that those produced in
our lab behave similarly to the kisspeptins synthesized by chemical means. This research
was funded by Synthetic Biomanufacturing Institute, Utah State University (USU).
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CHAPTER 1
INTRODUCTION
Kisspeptins are an arginine-phenylalanine-amide family of neuroactive peptide
hormones expressed by the KISS1 gene, which along with their cognate receptor GPR54,
are vital to the pubertal phase of growth during teenage years and the completion of
puberty thereafter [1]. Kisspeptins modulate the final common pathway for the neuronal
control of reproduction that initiates puberty, influence sexual dimorphism of the brain
and the regulation of gonadotropin secretion in adults [2]. The discovery of kisspeptins’
role in initiation of puberty has been hailed as a milestone in the history of reproductive
physiology. This finding has been compared in importance to the discovery of
gonadotropin release hormone (GnRH) in 1977 [3].
Epidemiology and pathophysiology of kisspeptin disorders
Kisspeptin signaling defects underlie major reproductive disorders. Loss of
function GPR54 mutations are associated with sporadic and familial normosmic
idiopathic hypogonadotropic hypogonadism in humans [4]. 1-10 in 100,000 births are
affected by congenital hypogonadotropic hypogonadism [5]. An activating mutation of
GPR54 leading to prolonged activation of kisspeptin signaling pathway results in
precocious puberty [6]. In an epidemiological study conducted in the Danish population,
precocious puberty was found to affect 0.2% of all girls [7]. One of the most prevalent
endocrine disorders in women, polycystic ovarian syndrome (PCOS), is associated with
increased plasma kisspeptin levels [8].
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KISS1 gene was originally discovered by subtractive hybridization as a metastasis
suppressor in human melanoma cells and has been found to inhibit metastasis of
melanoma, breast cancer, and ovarian cancers [9, 10]. Kisspeptins block the final
colonization step in the metastatic cascade [11]. Our preliminary phosphoinositide profile
experiments showed suppression of glycerophosphoinositide-(4,5)-bisphosphate levels in
kisspeptin-expressing melanoma cells compared to the controls. Reduction in
phosphoinositide-(4,5)-bisphosphate (PtdIns(4,5)P2) levels has been associated with
metastasis suppression [12]. Since more than 90% of deaths from cancers occur from
metastases [13], metastatic suppression by kisspeptins holds therapeutic potential in
managing cancer.
KISS1 and the gene encoding the GPR54 receptor are primarily expressed in the
placenta, hypothalamus, gonads, liver and pancreas [14]. Kisspeptins are proposed to act
as a conduit to relay the nutritional status of an individual to the reproductive system [2].
During decreased food intake this may help shunt the body’s energy resources from
reproduction to more immediate functions. Negative energy balance is associated with
reduced KISS1 expression in the central nervous system [2]. Administration of
kisspeptins resulted in the increased release of the reproductive hormones in rats with
negative energy balance [15]. Leptins, secreted in proportion to a body’s white adipose
tissue stores, directly stimulate hypothalamic neurons that release kisspeptins [16].
Kisspeptins in turn stimulate other central nervous system neurons to release GnRH [2].
Leptins are also hypothesized to be an important metabolic regulator of kisspeptin
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expression in the hypothalamus [2]. Therefore, kisspeptin, along with leptins, may have
therapeutic applications in reproductive disorders like hypothalamic amenorrhea [17].
Characterization of kisspeptins
Kisspeptins are a family of structurally related neuroactive peptides encoded by
the metastasis-suppressor KISS1 gene [2]. The structural features of the kisspeptins are
illustrated in Fig. 1-1. The KISS1 gene, which has been mapped onto chromosome 1, is
composed of four exons – the first two are non-coding and the other two encode the 145
amino acid length KISS1 protein [18]. Kisspeptins are derived from sequential
proteolytic processing by prohormone convertases at the dibasic cleavage sites of the 145
amino acid KISS1 protein [19]. The C-terminal residue of the initial 54-amino acid long
cleavage product gets is amidated presumably by peptidyl-glycine-α-amidating
monooxygenase (PAM) to form an arginine-phenylalanine-amide (RF-NH2) [19].
Smaller kisspeptin fragments of 14- and 13-amino acids sharing the amidated carboxyterminal, have been identified by mass spectroscopy in placental fractions exhibiting
kisspeptin activity [20]. A 10-amino acid long kisspeptin was discovered in cell culture
media conditioned by first trimester human trophoblasts [21]. For descriptive purposes
kisspeptins are abbreviated as ‘kp’ followed by a number denoting the amino acid length
[20].
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Fig. 1-1 Structural features of kisspeptins. KISS1 represents the 145 amino acid fulllength kisspeptin. Kisspeptin-54 is produced by cleavage of the 67th amino acid and the
cleavage and terminal amidation at the 121st amino acid. Mechanisms underlying the
processing of kisspeptin-14, -13 and -10 remains unclear [2]. Kisspeptins are not drawn
to scale.

Choice of kisspeptin-54 for production in bacterial systems
Kisspeptins synthesized biologically or chemically have the potential to be used
as experimental reagents and future therapeutic agents. The most common kisspeptin
used as an experimental reagent is kisspeptin-10. Chemically synthesizing kisspeptin-10,
-13 and -14 in large quantities is feasible technically and economically. However,
kisspeptin-54 has been found to have biological effects distinct from kisspeptin-10
warranting its production for additional experimental and future therapeutic applications.
Kisspeptin-54 is the major kisspeptin present in human circulation [22]. Kisspeptin-54
has shown a broader testosterone secretion peak effect than shorter kisspeptins [23]. A
broader testosterone secretion peak indicates a more prolonged effect on testosterone
secretion. The longer half-life of the rodent analog of kisspeptin-54 compared to the
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smaller kisspeptins may have resulted in a larger integrated luteinizing hormone (LH)
response in rats [24]. Administration of kisspeptin-54 increased LH secretion in women
suffering from hypothalamic amenorrhea [17]. Subcutaneous administration of
kisspeptin-54 increased the LH pulsatility in healthy female adult volunteers and may be
helpful in managing LH dysregulation underlying infertility [25]. These findings make a
strong case for production of kisspeptin-54 for therapeutic applications. The longerlasting stimulatory properties of the kisspeptin-54 may be leveraged in future diagnostic
tests for localizing the lesion in hypothalamic-pituitary-gonadal axis and evaluating
patient’s gonadotropic potential [2]. Though the full-length KISS1 has been expressed in
mammalian cells to understand the effects of KISS1 expression [11, 26], to our
knowledge it has not been expressed in high levels in bacterial systems for large-scale
production or its effects extensively studied. Unfortunately, the large-scale chemical
synthesis of the larger kisspeptin, kisspeptin-54, and the full length KISS1 is expensive
and challenging. Previous work done on the expression of kisspeptin-54 in E. coli
required a large array of expensive equipment and called for a large number of
purification steps making it a challenge to scale-up [27, 28]. The chemically synthesized
kisspeptin-54 available for purchase is expensive. There is, therefore, a need to develop a
simple and cost-effective approach for the synthesis of the larger kisspeptins and we feel
that this can be achieved using bacterial expression systems.
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Kisspeptin signaling
The GPR54 kisspeptin receptor is a seven-transmembrane domain Gαq/11-protein
coupled receptor [29]. Stimulation of GPR54 by kisspeptin binding activates the Gαq/11
G-proteins, resulting in a pertussis toxin-independent rise in intracellular calcium but
with no effect on cAMP levels [29]. G-protein coupled receptor (GPCR) proteins act as
signal transducers of extracellular environmental signals to activate kinases such as
extracellular-signal-regulated kinases 1 and 2 (Erk1/2) and Akt, stimulating cellular
proliferation and migration associated with metastasis [30]. The phosphorylation pathway
of Erk1/2 and Akt from stimulation of GPR54 by kisspeptin-54 is shown in Fig. 1-2.
Activated G-proteins recruit and activate phospholipase C (PLC), the enzyme responsible
for the hydrolysis of phosphoinositide-(4,5)-bisphosphate (PtdIns(4,5)P2) into inositol
1,4,5-trisphosphate (Ins(1,4,5)P3) and diacylglycerol (DAG). The Ins(1,4,5)P3) initiates
the release of intracellular calcium (Ca2+) from the endoplasmic reticulum (ER). The rise
in intracellular Ca2+ and DAG activates protein kinase C (PKC) that in turn causes
phosphorylation of mitogen-activated kinases (MAPK) like Erk1/2. Activation of the Gα
subunit also facilitates activation of Akt through phosphatidylinositol-3-kinase [31].
Kisspeptins have also been found to act through GPR54 using G-protein
independent mechanisms. β-arrestin-2 has been found to promote Erk1/2 phosphorylation
in human breast adenocarcinoma cell line MDA-MB-231 [32], whereas β-arrestin-1 has
an inhibitory effect [33]. It is of importance to note that the intracellular kinase response
to kisspeptin stimulation is dependent on the cellular context. The phosphorylation of
Erk1/2 is the most universally conserved signaling response to kisspeptins [34]. Chinese
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hamster ovary (CHO) cells transfected with the GPR54 receptor show prolonged
phosphorylation of Erk1/2 but no phosphorylation of stress-activated protein kinase/cJun-terminal kinase (SAPK/JNK) [20]. In response to kisspeptin treatment p38 MAP
kinase was activated in human pancreatic duct epithelial carcinoma (PANC-1) and CHO
cell lines, whereas no activation was seen in human anaplastic thyroid (ARO) and
pancreatic adenocarcinoma (AsPC-1) cell lines [35, 36]. Though studies in cellular
signaling underlying the actions of kisspeptins are being actively pursued, the focus of
kisspeptin research remains on the neuroendocrine and reproductive aspects of kisspeptin
physiology [2].

Fig. 1-2 Erk1/2 and Akt phosphorylation by kisspeptin-54. Erk1/2 is activated by PKC
and intracellular calcium. The mechanism underlying the phosphorylation of Akt by
kisspeptin-54 in Chinese hamster ovary cells expressing GPR54 is not known.
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Hypothesis
Our hypothesis is that the bacterially synthesized kisspeptin-54 will activate a
cellular signaling pathway associated with metastasis similar to the chemically
synthesized peptide. This hypothesis will be tested by biological assays examining the
activation of metastasis associated proteins Erk1/2 and Akt. The overall goal of this study
is to develop a simple and scalable method for the expression and purification of
biologically active kisspeptin-54 using bacterial systems, and, then using those
kisspeptins to develop a bio-activity assay using a heterologous cell system expressing
the kisspeptin receptor.
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CHAPTER 2
MATERIALS AND METHODS
Kisspeptin gene constructs – cloning and transformation
The kisspeptin gene constructs were designed using GeneDesigner 2.0 software
(DNA 2.0, Menlo Park, CA). Table 2-1 lists the constructs and their expression in the
Luria-Bertani broth (LB). The amino acid sequences used in the kisspeptin constructs are
described in the Fig. 2-1 and a schematic representation of the kisspeptin protein is
shown in Fig. 2-2. Codon optimization for E. coli was done using Gene Designer 2.0
(DNA 2.0, Menlo Park, CA) and the proprietary algorithm by DNA 2.0 [37]. Our initial
goal was to secrete the expressed kisspeptins into the extracellular or periplasmic space
for less intracellular degradation, better folding and easier recovery. The presence of
secretion tags has also been associated with higher protein expression [38]. The 21 amino
acid E. coli OmpA secretion signal sequence was therefore added to the 5’ end of the
kisspeptin-54 sequence. Cysteine was added after the kisspeptin-54 sequence for Cterminal amidation. The cysteine sulfhydryl group can be cyanylated and hydrolyzed to
produce C-terminally amidated peptide [27, 39]. A tobacco etch virus (TEV) cleavage
site between the kisspeptin-54 sequence and the 6xHis was added to release the peptide
from the purification tag in case of unsuccessful amidation. All the constructs have either
a N- or C-terminal tag of six contiguous histidines (6xHis) for purification. The peptides
with the polyhistidine tags can be purified by forming affinity complexes with the nickel
substrate in the chromatography matrices and separated from the proteins in E. coli [40].
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Omp-A
MKKTAIAIAVALAGFATVAQA
Kisspeptin-54 (kp-54)
GTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRF
KISS1
MNSLVSWQLLLFLCATHFGEPLEKVASVGNSRPTGQQLESLGLLAPGEQSLPCTE
RKPAATARLSRRGTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVLVQREKDLPN
YNWNSFGLRFGKREAAPGNHGRSAGRGWGAGAGQ
TEV cleavage site
ENLYFQG
Fig. 2-1 Amino acid sequences used in the kisspeptin constructs. The genes for the
peptide amino acid sequences were synthesized and inserted into the pJexpress 404
vector. The kisspeptin-54 (kp-54) and KISS1 sequences were obtained from the NCBI’s
website (GenBank Accession ID: U43527.1) and the Omp-A and TEV cleavage sites
sequences were from DNA 2.0 (Menlo Park, CA).

Since we did not know in advance about the toxicity of kisspeptins to the bacteria
we wanted a vector with minimal leakage for protein expression. DNA 2.0’s
pJexpress404 vector was chosen for symmetrical lac operators on both sides of the T5promoter [41], to provide maximum cooperativity thereby reducing leaky expression
[42]. The promoter selected for the construct, T5, is inducible by isopropyl β-D-1thiogalactopyranoside (IPTG), repressible, and free from intellectual property
restrictions. The pUC origin leads to high-copy number (approx. 150 – 200 copies/E.
coli) of plasmids in E. coli.
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The constructs were synthesized at DNA 2.0 and the lyophilized plasmid with the
cloned insert was shipped to our lab (Appendix A). On receiving the plasmid the
lyophilized DNA was dissolved in tris-ethylenediaminetetraacetic acid (Tris-EDTA)
buffer (10mM Tris at pH 8.0 and 1mM EDTA) to a 50ng/µl working concentration.

Fig. 2-2 Schematic representation of the kisspeptin-54 gene construct designed using
GeneDesigner 2.0. In the figure lac01 and lac0i stand for lac operators, IS1 and IS2 are
intervening sequences present in the pJexpress 404 vector, RBS for ribosome binding
site, pSS-OmpA for OmpA secretion signal tag, KP-54 for kisspeptin-54, PCS-TEV for
Tobacco Etch Virus cleavage site, and N 6xHis for the 6xhistidine tag added to the Cterminal end. The GeneDesigner software is published by DNA 2.0 Menlo Park, CA

Transformation was performed using 50µl of New England Biolabs Express
Competent BL21 E. coli cells (New England Biolabs, Ipswich, MA) with 100ng of the
kisspeptin construct. Untransformed E. coli and E. coli transformed with an empty
pUC19 vector (New England Biolabs, Ipswich, MA) were used as controls. The mixture
was incubated on ice for 30min and heat-shocked at 42°C for 20s and then placed on ice
for 5min. After adding 950ml of Super Optimal Broth with Catabolite repression (SOC)
the mixture was shaken at 37°C for 1h. Serial dilutions of the mixture were performed in
a SOC solution (2% tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM
MgCl2, 10mM MgSO4 and 20mM glucose) and plated onto LB-agar plates with 50µg/ml
carbenicillin for overnight incubation at 37°C.
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Pilot expression and purification of kisspeptins
High level expression of kisspeptins
Four colonies were picked from the LB-agar plate and inoculated into LBcarbenicillin media (50µg/ml carbenicillin) for overnight growth. The E. coli with the
kisspeptin constructs was grown to an optical density measured at 600nm (OD600) of 0.6
and split into equal volumes in two sterile flasks. One of the flasks was induced with
1mM IPTG whereas the other remained non-induced. Samples were taken at 0, 1, 3 and 5
hours. The E. coli pellets from the samples were suspended in B-PER Protein Extraction
Reagent (Thermo Fisher Scientific, Rockford, IL) supplemented with 1% Halt Protease
Inhibitor Cocktail (Thermo Fisher Scientific, Rockford, IL), 100µg/ml of lysozyme
(Thermo Fisher Scientific, Rockford, IL) and 5U of deoxyribonuclease (DNAse) I
(Thermo Fisher Scientific, Rockford, IL). The mixture was incubated at room
temperature for 10 – 30min on a shaking platform and then centrifuged at 15,000g for 1020min. The supernatant containing the soluble protein fraction was saved for sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis (Bio-Rad,
Hercules, CA). The pellet was re-suspended in Tricine Sample Buffer (Bio-Rad,
Hercules, CA), boiled for 15min, and loaded onto a 16.5% Ready-Gel Tris-tricine gel for
polypeptides (Bio-Rad, Hercules, CA) for analysis. Tris/tricine/sodium dodecyl sulfate
buffer (Bio-Rad, Hercules, CA) was used as the running buffer to perform the SDSPAGE and the 3,800–36,400kDa range Kaleidoscope Polypeptide Standards (Bio-Rad,
Hercules, CA) was used as the molecular weight reference ladder. The above mentioned
procedure was repeated with the soluble fraction of the E. coli cell lysis, the periplasmic
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fraction of the E. coli obtained using a 20% sucrose solution, the LB-carbenicillin media
used for growing the E. coli. Only the insoluble fraction of the E. coli with kisspeptin-54
construct showed high level expression in the SDS-PAGE gels. Table 2-1 lists the
constructs and the results of IPTG induction as assessed by SDS-PAGE.
Identification of the peptide expressed in high levels
The resolved proteins from the above-described fractions of the E. coli expressing
kisspeptins were transferred overnight from the Tris-tricine SDS-PAGE for polypeptides
gels to a nitrocellulose membrane at 25mA current. The nitrocellulose membrane was
then washed in Tris-buffer saline with 0.05% Tween-20 (TBS-T) with 5% non-fat dry
milk at room temperature for an hour. The membranes were then probed overnight with a
1:1000 dilution of anti-kisspeptin antibody (Santa Cruz Biotechnology, Dallas, TX) and
1:500 dilution anti-6xHis antibodies (Santa Cruz Biotechnology, Dallas, TX). Secondary
antibody incubation was done at room temperature for 1 hour using a 1:5000 dilution of
horseradish peroxidase conjugated antibodies. The signals were visualized on X-ray film
using the enhanced chemiluminescent (ECL) reagent according to the manufacturer’s
instructions (General Electric Healthcare, Buckinghamshire, United Kingdom). The antikisspeptin immunoblots exhibited high non-specific binding and the anti 6xHis
immunoblots showed a very weak signal after 30min exposure of the film. Unable to get
a good signal with the immunoblotting it was decided to cut out the band expressed at
high levels from the SDS-PAGE of the insoluble fraction and send it for mass
spectroscopic analysis at Alphalyse (Alphalyse, Palo Alto, CA).
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Bench-top purification of the kisspeptins
Kisspeptin-54 was purified under both native and denaturing conditions using the
nickel-nitrilotriacetic acid (Ni-NTA) Fast Start Kit (Qiagen, Valencia, CA). The peptides
were purified in significantly greater amounts under the denaturing conditions. The cell
pellet was resuspended in a denaturing lysis buffer (8M Urea, 100mM NH2PO4, 100mM
Tris.Cl, pH 8.0), incubated at room temperature for an hour with occasional shaking, and
then centrifuged at 14,000g for 30min. The cell pellet was discarded and the cell lysate
loaded onto the Ni-NTA column. The column was washed twice with denaturing wash
buffer (8M Urea, 100mM NH2PO4, 100mM Tris.Cl, pH 6.3) and the kisspeptins eluted
with the denaturing elution buffer (8M Urea, 100mM NH2PO4, 100 mM Tris.Cl, pH 4.5).
The peptides in the cell lysate, flow-through, wash and elution fractions were resolved on
a Tris-tricine SDS-PAGE for polypeptides. From the elution fractions bands
corresponding to the molecular weight of the kisspeptin-54 were cut out and sent for
protein identification by mass spectroscopy at Alphalyse.
Preliminary biological assay with the purified unamidated kisspeptin-54
Mammalian cells expressing the human GPR54 for biological assays
For biological assays we obtained CHO-G (CHO cells with the kisspeptin GPR54
receptor on a pIRESneo3 vector) and CHO-0 (CHO cells with an empty pIRESneo3
vector). The CHO-G and CHO-0 cells were a gift from Dr. Ursula B. Kaiser of Brigham
and Women’s Hospital, MA. The receptor was characterized in a study using these CHOG cells for high throughput screening for kisspeptin agonists and antagonists [43]. The
CHO cells transfected with the empty vector (CHO-0), were used as controls. The cells
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were maintained in Dulbeco’s Modified Eagle Medium F-12 (DMEM/F-12) (Thermo
Fisher Scientific, Rockford, IL), 10% fetal bovine serum (FBS) (Thermo Fisher
Scientific, Rockford, IL), 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO),
and 800µg/ml of geneticin (Sigma Aldrich, St. Louis, MO). The cells were grown in a
sterile incubator (New Brunswick, Edison, NJ), maintained at 37°C and supplied with 5%
CO2.
Chemically synthesized kisspeptins
Kisspeptin-54 (kp-54) and kisspeptin-10 (kp-10) were obtained from Phoenix
Pharmaceuticals, Burlingame CA. The kisspeptin-54 synthesized by the above mentioned
supplier has been used to study depolarization of hypothalamic gonadotropin-hormone
releasing neurons [44], kisspeptin-like immunoreactivity in human adrenal glands and
adrenal tumors [45], and release of luteinizing hormone (LH) in response to kisspeptin-54
injections in mice [46, 47]. The kisspeptin-10 from the same company has been used to
study the role of kisspeptins and GPR54 in invasiveness in MDA-MB-231 and Hs578T
breast cancer cell lines [48]. The biological activities of the kisspeptin-54 synthesized in
E. coli were compared with kisspeptin peptides produced by chemical methods.
Effect of purified unamidated kisspeptin-54 on cell proliferation
We tested the effects of the purified unamidated kisspeptin-54 on cell
proliferation of the CHO-G and CHO-0 cells. Though amidation is required for the
optimal effect of the kisspeptins [28], unpublished experiments found unamidated
kisspeptins to have effects on the cellular properties (Danny Welch, University of
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Kansas, personal communication). The cell proliferation was measured using tetrazolium
dye which changes color due to electron transfer from the functional mitochondria in a
living cell [49]. The degree of color change of the 2,3-Bis(2-methoxy-4-nitro-5sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium (XTT) salt solution (ATCC,
Manassas, VA) is read by a spectrophotometer as an indicator of the number of viable
cells the solution is in contact with [50]. We chose to use the XTT assay over the (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) MTT assay (ATCC Manassas
VA) as the former, on following the manufacturer’s protocols, requires less manipulation
and thereby presents less chance of error. CHO-G and CHO-0 cells were seeded onto a
96 well plate at a concentration of 1 x 105 cells/ml. After 24-hour incubation the cells
were serum starved overnight and treated with 1µM unamidated kisspeptin-54
synthesized in the lab, 1µM kisspeptin-54 (Phoenix Pharmaceuticals, Burlingame, CA),
and 1µM kisspeptin-10 (Phoenix Pharmaceuticals, Burlingame, CA) for 12h each.
Untreated CHO-G and CHO-0 cells as well as the cell culture media were used as
controls. Six replicates of each cell line were used for each treatment or as controls. After
the kisspeptin treatment the XTT solution was added to the wells and the plate was
incubated for 3h. Absorbance of the wells was then measured at 475nm and the plate
reader was zeroed using values from the wells containing only media. Absorbance was
then measured again at 660nm and the values subtracted from the 475nm measurement to
remove any non-specific readings.
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Production of kisspeptin-54 in 5L fermenters
E. coli with kisspeptin-54 constructs were grown in 100ml of LB-carbenicillin
media (50µg/ml carbenicillin) overnight and used to inoculate 2L of LB-carbenicillin
media in a bench-top fermenter (New Brunswick, Edison, NJ). The temperature was
maintained at 37°C, the dissolved oxygen concentration at 30 - 40% and the pH at 7 – 8.
Once the OD600 was between 0.5 and 0.8, 1mM IPTG was used to induce the culture. The
cells were harvested approximately 5h after induction with an OD600 between 3 and 4.
Purification of kisspeptin-54 using fast protein liquid chromatography
Kisspeptin purification on a Ni-NTA column
In spite of lower yields, concerns about the protein folding led us to pursue
purification of the kisspeptin-54 with a non-denaturing protocol using the 5ml Ni-NTA
Superflow Cartridges (Qiagen, Valencia, CA) on Äkta Avant and Äkta Explorer Fast
Protein Liquid Chromatography (FPLC) systems (General Electric Healthcare,
Buckinghamshire, United Kingdom). E. coli cell pellets from the 2L fermentation were
thawed and resuspended in 2ml of lysis buffer (50mM NaH2PO4, 300mM NaCl, 10mM
Imidazole, pH 8.0) per gram wet weight. 1mg/ml lysozyme, 1% Halt Protease Inhibitor
Cocktail and 3U/ml of original culture volume Benzonase Nuclease (Thermo Fisher
Scientific, Rockford, IL) were added to the cell lysates. The cell lysis mixture was
sonicated 10 times at 15W bursts of 25s duration and 30s cooling period in between.
Approximately 40ml of cell lysate was loaded onto the 5ml Ni-NTA columns and washed
with 10 column volumes of the mixture of lysis and elution buffer with a 20mM
imidazole concentration. The bound 6xHis peptides were eluted with 5 column volumes
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of the elution buffer (50mM NaH2PO4, 300mM NaCl, 250mM imidazole, pH 8.0). The
elution fractions corresponding to the peaks for the protein of interest were analyzed on
Tris-tricine SDS-PAGE for polypeptides. The total protein concentration was estimated
using the bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Rockford,
IL). The elution fractions were collected and analyzed on dot blots and Tris-tricine SDSPAGE for polypeptides. For the dot-blots 30µl of the wash and elution fractions were
applied to a nitrocellulose membrane. The membrane was then incubated in Tris-buffer
saline with 0.05% Tween-20 (TBS-T) with 5% non-fat dry milk for approximately
30min. The membrane was probed with a 10,000x dilution anti-6xHis antibody
(Rockland Immunochemicals, Gilbertsville, PA) for 30min, followed by a 10,000x
dilution of alkaline phosphatase-conjugated secondary antibody (Abcam, Cambridge,
MA) for another 30min. The membrane was then developed with nitro-blue tetrazolium
chloride (NTB)/ 5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt (BCIP) (Thermo
Fisher Scientific, Rockford, IL) for 5 – 15min. The fractions with kisspeptin-54 stained
purple. The purity of the kisspeptins in the elution fractions analyzed via SDS-PAGE was
estimated using ImageJ software (National Institutes of Health, Bethesda, MD). To
estimate the purity the SDS-PAGE gels images were loaded onto the ImageJ software.
The background intensity was subtracted from the signal intensity of the peptide bands in
the SDS-PAGE well loaded with the elution fraction. The signal intensity from the
kisspeptin-54 band was then calculated relative to all other peptide bands present in that
particular elution fraction to gives us the approximate purity of the kisspeptin-54.
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To improve the purity of the kisspeptin-54 it was decided to load the column
multiple times with the cell lysate and attempt column washing by varying the imidazole
concentrations in a step-wise manner or as a gradient of 5mM to 78.5mM imidazole. The
gradient washes started producing kisspeptins with approximately 80% purity. To
increase the kisspeptin yield it was decided to add 6M urea to the lysis and the elution
buffers to solubilize the insoluble protein we knew was present in the cell extracts. With
the above-mentioned changes we were able to increase the yield and achieve 90% purity.
However, we were still unable to remove some of the higher molecular weight impurities
persistent in all the elution fractions. We tried size exclusion chromatography (SEC) and
the reversed phase chromatography. The SEC was determined not to be a viable option
and reversed phase chromatography was pursued.
Kisspeptin purification on a reversed-phase FPLC column
The eluted kisspeptins from the Ni-NTA purification were loaded onto a 3ml
mixed-bed resin reversed phase (RP) column (General Electric Healthcare,
Buckinghamshire United Kingdom) connected to a reversed phase fast protein liquid
chromatography (RP-FPLC) system. The RP-FPLC experiments were done on Äkta
Avant and Äkta Explorer systems mentioned previously. The sample from the Ni-NTA
elution fraction was diluted in nanopure H2O with 0.1% trifluoroacetic acid (TFA). The
two elution mobile phases were composed of 0.1% TFA dissolved in nano-pure water
and 0.1% TFA in neat acetonitrile. The column was washed with 10% acetonitrile (+ 1%
TFA) for 4 column volumes, a gradient of 10 – 50% acetonitrile (+ 1% TFA) for 16
column volumes, another gradient of 50 – 100% acetonitrile (+ 1% TFA) for 2 column
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volumes and held at 100% acetonitrile (+ 1% TFA) for 2 column volumes. The elution
fractions were collected, lyophilized, and analyzed on Tris-tricine SDS-PAGE for
polypeptides.
Mid-scale expression of the kisspeptin-54 in a 20L bioreactor
Kisspeptin expression scale-up was done in a 20L Winpac bioreactor and
fermenter (GMI, St. Paul, MN). For the scale-up it was decided to use a media richer in
nutrients than LB. ZY media composed of Hy Express System II (Sheffield Bio-Science,
Beloit, WI) and yeast extract was chosen based on the high growth of E. coli observed
with the bacterial production of other biomaterials in the lab [51]. Pilot experiments with
the growth of E. coli containing the kisspeptin-54 constructs showed higher cell density
compared to LB media for the same growth period.
E. coli containing the kisspeptin constructs were grown in 20L of ZY media
supplemented with a carbon source (dextrose and glycerol), phosphates, sulfates and
trace minerals. Carbenicillin for the overnight seed culture and ampicillin for the
fermentation provided the antibiotic selectivity. Composition of the growth media and the
concentration of trace minerals used in the bioreactor are listed in the tables 2-1 and 2-2.
Induction was provided by lactose added by peristaltic pump 4h after inoculation.
Fermentation at the 20L scale yielded 701.3g of wet bacterial cell paste.
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Table 2-1 Composition of the media used for mid-scale fermentation
Chemical, compound or mixture
Amount
Hy Express System II
200g
Yeast extract (containing vitamin B complex)
100g
Carbon source mix:
Dextrose
44g
Lactose (pumped in after 4h for inducing the kisspeptin-54
40g
expression
Phosphates/sulfates:
Ammonium sulfate ((NH4)2SO4)
66g
Monopotassium phosphate (KH2PO4)
136g
Disodium phosphate (Na2HPO4)
142g
Magnesium sulfate heptahydrate (MgSO4 7H2O)
9.86g
Ampicillin
2g
Trace mineral 1000x stock (Table 2-3)
20ml
Except for Hy Express System II (Sheffield Bio-Science, Beloit, WI) the chemicals were
purchased from Thermo Fisher Scientific, Rockford, IL and Sigma Aldrich, St. Louis,
MO.

Table 2-2 Composition of the trace mineral stock solution
Trace mineral
Amount
Iron (III) chloride (FeCl3)
13.5g
Calcium chloride (CaCl2)
2.94g
Manganese (II) chloride (MnCl2)
1.97g
Zinc chloride (ZnCl2)
2.876g
Cobalt (II) chloride (CoCl2)
0.476g
Copper (II) chloride (CuCl2)
0.341g
Nickel (II) chloride (NiCl2)
0.475g
Sodium molybdate (Na2MoO4)
0.484g
Sodium selenate (Na2SeO4)
0.526g
Boric acid (H3BO3)
0.124g
The minerals are dissolved in sterile water to form 100ml of the 1000x stock solution and
then purified using a 0.2µm sterile filter. The minerals were purchased from Thermo
Fisher Scientific, Rockford, IL and Sigma Aldrich, St. Louis, MO.
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Purification of the kisspeptin-54 on 100ml Ni-NTA and RP-FPLC columns
Approximately 200g of the E. coli wet cell paste from the 20L fermentation was
resuspended in 600ml lysis buffer (6M Urea, 50mM NaH2PO4, 300mM NaCl, 5mM
Imidazole, pH 8.0) and sonicated in an ice bath at 80W for four 10min bursts and
intervening 5min cooling periods. It was decided to not use the protease inhibitor
cocktail, lysozyme and DNAse in order to decrease the compounds that need to be
removed from the cell lysate. The cell extract was then centrifuged at 9000g for a total of
3h at 4°C. Approximately, 700ml of the cell lysate was recovered after removal of the
debris. The cell lysate was then diluted with three volumes of lysis buffer before loading
onto the 100ml settled bed volume Ni-NTA column (General Electric Healthcare,
Buckinghamshire, United Kingdom) connected to an Äkta Avant FPLC system. The
column was loaded three times each from both ends and then washed successively with
100% lysis buffer for 10 column volumes, 10% elution buffer (6M Urea, 50mM
NaH2PO4, 300mM NaCl, 250mM Imidazole, pH 8.0) mixed with 90% lysis buffer for 10
column washes, and 18% of the elution buffer mixed with 82% lysis buffer for another 10
column washes. The column bound peptides were eluted with the five column volumes of
100% elution buffer. The elution fractions were collected in the 4°C chamber holding the
fraction rack and analyzed on the Tris-tricine SDS-PAGE for polypeptides.
Elution fractions containing kisspeptins were pooled and loaded with the aid of
the software programmed for repeated injections on to the 3ml mixed-bed resin reversed
phase columns. As described above, the column was washed with a 0 – 30% acetonitrile
(+ 1% TFA) gradient for 1 column volume, held at 30% acetonitrile (+ 1% TFA) for 4
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column volumes and then washed again with a 30 – 100% acetonitrile (+ 1% TFA)
gradient for 1 column volume and held at 100% acetonitrile (+ 1% TFA) for 2 column
volumes. The fractions were lyophilized and analyzed using Tris-tricine SDS-PAGE for
polypeptides gels.
The RP-FPLC elution fractions exhibited higher molecular weight peptides in the
Tris-tricine SDS-PAGE for polypeptides. The molecular weight of the peptides indicated
that they might be multimers of the kisspeptin-54 probably formed by disulfide bonds
between cysteines in adjacent kisspeptin-54 peptides. The kisspeptin-54 from the RPFPLC was dissolved in the amidating buffer (6M Urea, 0.1M acetic acid) with and
without β–mercaptoethanol (Sigma Aldrich, St. Louis, MO) and analyzed on Tris-tricine
SDS-PAGE gel for polypeptides.
Kisspeptins to be used as unamidated kisspeptins were dissolved in buffer
consisting of 6M urea and buffer-exchanged into phosphate buffer saline (PBS) using a
2000 dalton molecular weight cutoff (MWCO) membrane (Millipore, Santa Clara, CA).
C-terminal amidation of the kisspeptin-54
The C-terminal amidation reaction occurs at the cysteine in the polypeptide chain
[27, 39]. The sulfhydryl group of cysteine gets converted to thiocyanate by 1-cyano-4(dimethylamino) pyridinium tetrafluoroborate (CDAP) (Sigma Aldrich, St. Louis, MO).
Initially the lyophilized kisspeptins in amidating buffer (6M Urea, 0.1M acetic acid) were
treated with 5mM CDAP for 20min. The cysteine specific cleavage reaction of the
cyanylated protein using 3M ammonia was subsequently carried out for an hour to
release the amidated peptide. The amidation reaction was analyzed using a C18 column
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(General Electric Healthcare, Buckinghamshire, United Kingdom) on a Waters Acquity
ultra performance liquid chromatography (UPLC) system (Waters Corporation, Milford,
MA). Successfully amidated kisspeptin-54 should be seen as a peak shifted from the
unamidated kisspeptin-54 in the UPLC peaks. However, the above reaction parameters
were yielding incomplete amidation products, seen as peak broadening rather than as a
complete peak shift. It was therefore decided to increase the CDAP concentration and
treatment. Lyophilized kisspeptins in 6M urea and 0.1M acetic acid were now treated
with 15mM CDAP for 90min. This treatment was repeated twice. The cleavage reaction
was then carried out for 2h. After peptide cleavage the peptide sample was buffer
exchanged with 15L of PBS over the course of 48h to remove the 6M urea. A small
amount of the cyanylated kisspeptin-54 after the cleavage reaction was buffer exchanged
with 50mM ammonium bicarbonate and then lyophilized. The lyophilized amidated
kisspeptin-54 was then sent for matrix assisted laser desorption/ionization – time of flight
(MALDI-TOF) mass spectroscopic analysis.
Biological assays for the kisspeptins
To test the biological activity of the amidated and unamidated kisspeptins we
decided to study the effects of kisspeptin-54 on the Erk1/2 and Akt phosphorylation in
CHO cells expressing the GPR54 kisspeptin receptor (CHO-G) [20]. The Erk1/2
phosphorylation has been found to be the most common phosphorylation effect produced
by kisspeptins on various cell types. The kisspeptins are not known to phosphorylate Akt
in the CHO-G cells [52]. Kisspeptin-54 synthesized by chemical means by Phoenix
Pharmaceuticals (Burlingame, CA) was used as a control.
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CHO-G and CHO-0 cells were grown to 80% confluency in 100mm plates under
the conditions described above and then serum-starved overnight. The cells were treated
with amidated biologically synthesized kisspeptin-54, unamidated biologically
synthesized kisspeptin-54 and chemically synthesized amidated kisspeptin-54 for 10min.
For the Erk1/2 experiments 1µM kisspeptin-54 and for the Akt experiments 250nM
kisspeptin-54 concentrations were used. The cells were washed twice with ice-cold
Dulbeco’s Phosphate Buffer Saline (D-PBS) (Thermo Fisher Scientific, Rockford, IL).
1ml of Mammalian-Protein Extraction Reagent (M-PER) (Thermo Fisher Scientific,
Rockford, IL) mixed with 1% Protease/Phosphatase Inhibitor Cocktail (Cell Signaling
Technologies, Danvers, MA) was added to each plate. The plates were kept on ice and
shaken for 5min. The cells were scraped off the plates, spun down at 14,000g for 10min.
The supernatant was recovered, and the total protein concentration was determined using
the BCA assay (Thermo Fisher Scientific, Rockford, IL). The cell debris was discarded.
The proteins were mixed with Laemmli Sample Buffer (Bio-Rad, Hercules,
CA), incubated in a boiling water bath for 15min and then loaded onto a 4 - 20% Precise
Protein gels (Thermo Fisher Scientific, Rockford, IL) for resolution. The separated
proteins were then transferred onto nitrocellulose membranes using 100mA for 60min.
The proteins on the nitrocellulose membranes were blocked with Tris-buffered saline
containing 0.05% Tween-20 (TBS-T) and 5% dry non-fat milk (Thermo Fisher Scientific,
Rockford, IL). The membranes were probed overnight at 4°C with primary antibodies for
phospho-Erk1/2, phospho-Akt, and Histone H3 (all antibodies were from Cell Signaling
Technologies, Danvers, MA). As the molecular weight of phospho-Erk1/2 was similar to
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β-actin, Histone H3 was used as a loading control. Since we are not certain about the
Histone H3 differential expression levels in CHO-G and CHO-0 cells, the proteins from
the corresponding treatments were also run on SDS-PAGE gels and stained with
Coomassie (Bio-Rad, Hercules, CA) as additional loading controls. The membranes were
probed using HRP-conjugated secondary antibody (Cell Signaling Technologies,
Danvers, MA) at room temperature for 1h. The detected proteins were visualized using
the enhanced chemiluminscence (ECL) western blotting detection reagents as per the
manufacturer’s instructions (General Electric Healthcare, Buckinghamshire, United
Kingdom). Densitometry was done on a Gel Doc EZ System (Bio-Rad, Hercules, CA).
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CHAPTER 3
RESULTS
Pilot expression and purification of kisspeptins
Kisspeptin genes were synthesized at DNA 2.0 (Menlo Park, CA). We
transformed E. coli with the plasmid containing the kisspeptin gene and grew the cells in
LB-carbenicillin with 50µg/ml carbenicillin. Of all the kisspeptin constructs we worked
with, only the kisspeptin-54 construct with an OmpA secretion signal and C-terminal
6xHis showed high levels of expression by SDS-PAGE (Table 3-1).

Table 3-1 Kisspeptin constructs
Kisspeptin
Type of construct
Kisspeptin-54
OmpA, C-terminal 6xHis
Kisspeptin-54
N-terminal 6xHis
Full-length KISS1
C-terminal 6xHis
Full-length KISS1
OmpA, C-terminal 6xHis

Results
High expression
Low expression
Low expression
Low expression

High level expression of kisspeptins
E. coli cells containing kisspeptin constructs were grown in LB-carbenicillin
media and peptide expression was examined in the insoluble and soluble fractions of the
induced and non-induced E. coli cultures. Additionally, the periplasmic fractions and the
culture media were examined for the presence of kisspeptin.
________________________________________________________________________
Figures 3-20 and 3-21 provided by J.A. Jones
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High level expression of kisspeptins was seen only in the insoluble fraction of the
bacterial cell pellets. The molecular weight of the peptide expressed in high levels
(approximately 9.6 kilodaltons) corresponded to that expected for the kisspeptin-54
construct having the kisspeptin-54, OmpA secretion signal, protease cleavage site,
cysteine for cyanylation and the six histidine tag. High level expression of kisspeptin-54
became noticeable 3h post-induction, reached peak expression in 5h post-induction and
then tapered off in the next hour. The E. coli cells also started lysing approximately 5h
after induction using 1mM IPTG. Expression was analyzed using 16.5% Tris-tricine
SDS-PAGE for polypeptides (Fig. 3-1).

IPTG
0

1

No. of hours
post 1mM IPTG
induction

No IPTG
3

5

0

1

3

5

32,300 Da
24,950 Da
14,090 Da
7,681 Da
3,480 Da
Kp-54

Fig. 3-1 High level expression of kisspeptin after IPTG induction. Kisspeptins can be
seen in the IPTG induced fractions 3h and 5h after induction. In this figure, Kp-54 stands
for kisspeptin-54 with the OmpA secretion signal, protease cleavage site, cysteine for
cyanylation and the six histidine tag. The estimated molecular weight of the kisspeptin-54
peptide is 9.6 kilodaltons.
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Identification of the peptide expressed in high levels
The band expressed in high levels in the fraction 3h after induction was cut out of
the gel and sent to Alphalyse for MALDI-TOF/TOF mass spectroscopic analysis.
Fragments of the kisspeptin-54 taken from the gel covered 60% of the amino acids
predicted to be produced from the kisspeptin-54 construct. Each of these fragments
provided a perfect match to the modified kisspeptin-54 expected to be produced from the
kisspeptin-54 construct (Fig. 3-2). Bovine serum albumin (BSA) and transferrin were
used as controls. This confirmed that the expressed peptide was the expected peptide
from the gene used. The mass spectroscopic result is included in the dissertation as
Appendix B.

MKKTAIAIAVALAGFATVAQAGTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVL
VQREKDLPNYNWNSFGLRFCENLYFQGHHHHHH
Fig. 3-2 The amino acid sequence expected shown with the underscored amino acid
sequence of the residues was identified by MALDI-TOF/TOF. This demonstrated that the
band expressed in high levels is the predicted peptide.
Bench-top purification of kisspeptin-54
The insoluble fraction expressed in high levels was purified using the Ni-NTA
chromatography and the fractions were analyzed on Tris-tricine SDS-PAGE for
polypeptides as described above (Fig. 3-3). The bands in the two elution fractions
corresponding to the molecular weight of the kisspeptin were excised and sent to
Alphalyze for MALDI-TOF/TOF mass spectroscopic analysis. There was a 31% overlap

30
with the kisspeptin-54 sequence in one band whereas the other band showed 60%
sequence coverage, again confirming the correct protein (Fig. 3-4). Transferrin and
albumin precursor were used as controls. The mass spectroscopic result is included in the
dissertation as Appendix C.

CL

32,300 Da

FT

WF1

WF2

EF 1 EF2

Kp-54

24,950 Da
14,090 Da
7,681 Da

3,480 Da
Fig. 3-3 Coomassie stained Tris-tricine SDS-PAGE for polypeptides gel showing 6xHistagged kisspeptin-54 purified under denaturing conditions. In this figure, CL stands for
cell lysate, FT for flow-through fraction, WF1 for the 1st wash fraction, WF2 for the 2nd
wash fraction, EF1 for the 1st elution fraction and EF2 for the 2nd elution fraction, and
Kp-54 for kisspeptin-54.
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Band 1 sequence coverage (31%)
MKKTAIAIAVALAGFATVAQAGTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVL
VQREKDLPNYNWNSFGLRFCENLYFQGHHHHHH
Band 2 sequence coverage (60%)
MKKTAIAIAVALAGFATVAQAGTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVL
VQREKDLPNYNWNSFGLRFCENLYFQGHHHHHH
Fig. 3-4 The amino acid sequence identified in the two prominent bands (band 1 and band
2) in the elution fractions depicted in Fig. 3-3. The underscored amino acid sequences
were identified by MALDI-TOF/TOF.

Preliminary biological assay with the purified unamidated kisspeptin-54
Effects of purified unamidated kisspeptin-54 on cell proliferation
Kisspeptin-54 reduces the formation of CHO cell colonies in Bacto-agar by
expressing GPR54 in a dose-dependent manner [53]. Kisspeptin-10 is known to inhibit
the proliferation of CHO cells expressing GPR54 [20]. Therefore, we examined the effect
of unamidated kisspeptin-54 on the proliferation of CHO cells expressing GPR54 (CHOG).
We used a tetrazolium based assay to obtain an accurate estimate of the viable cell
count. The XTT assay shows that the unamidated kisspeptins produced in E. coli down
regulate cell-proliferation in CHO-G cells (Fig. 3-5). The unamidated kisspeptins show a
anti-proliferation effect similar to the chemically synthesized and amidated kisspeptin-54
and -10. This result adds support to the finding that unamidated kisspeptins show cellular
effects [28].
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Fig. 3-5 Biologically synthesized unamidated kisspeptin-54 behaves similarly to the
chemically synthesized and amidated kisspeptin-10 and kisspeptin-54. The application of
1µM kisspeptins reduces cell proliferation as measured by XTT assay of CHO-G cells
expressing the kisspeptin receptor. In the figure, E. coli KP-54 stands for our biologically
synthesized unamidated kp-54. Six replicates of each cell line were used for each
treatment. Error bars represent the standard deviation.

Production of kisspeptin-54 in 5L fermenters
Two liters of E. coli containing the kisspeptin-54 construct was grown in 5L
fermenters. Fig. 3-6 shows a representative growth in LB-carbenicillin (50µg/ml
carbenicillin) media with the following culture parameters - OD600, the amount of
dissolved oxygen in the media (DO%) and the pH. The culture was induced with 1mM
IPTG at an OD600 of 0.70. pH was maintained between 7 and 8. Care was taken to see
that the dissolved oxygen did not drop lower than 30%. The cells were harvested at an
OD600 of 3.50 approximately 5h after induction. Previous runs longer than 5h resulted in
the lysis of E. coli cells and concomitant foaming. The cell lysis and foaming indicates
that conditions became toxic for the growth of E. coli containing the kisspeptin-54.
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Fig. 3-6 Bio-reactor parameters for the growth of E. coli containing the kisspeptin-54
construct in a 2L culture. In the figure, OD represents optical density at 600nm, and
DO% represents the amount of dissolved oxygen in the LB-carbenicillin (50µg/ml)
media. The culture was induced at an OD600 of 0.70 and harvested at an OD600 of 3.50

Purification of kisspeptin-54 using fast protein liquid chromatography
Fast protein liquid chromatography (FPLC) provides a faster and more efficient
method of purifying the peptide of interest than bench-top gravitational flow affinity
column purification. Pellets of E. coli from the 2L fermentation runs were sonicated to
lyse cells, centrifuged, and the supernatant was then loaded onto 5ml Ni-NTA columns
connected to an FPLC system.
Kisspeptin purification on a Ni-NTA column
Ten milliliters of cell lysates was diluted with 30ml of the lysis buffer containing
10mM imidazole and injected onto a 5ml Ni-NTA column. The column was washed with
10 column volumes of buffer containing 20mM imidazole. The bound peptides were
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eluted with 250mM imidazole elution buffer (Fig. 3-7). The fractions were collected and
analyzed on Tris-tricine SDS-PAGE for polypeptides (Fig. 3-8).
The purity of the kisspeptin-54 seen in the Fig. 3-8 estimated by ImageJ was
approximately 4%. We implemented changes to our FPLC purification protocol to
increase the purity by reducing the concentration of imidazole in the lysis buffer from
10mM to 5mM. This was intended to bind more kisspeptin to the column and reduce the
non-specific binding of other peptides.
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Fig. 3-7. Absorbance at 280nm showing the protein peaks during the wash and elution
cycle of the FPLC. The wash for this FPLC was done with buffer containing 20mM
imidazole and the elution was performed using 250mM imidazole.
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24,950 Da
14,090 Da
7,681 Da
3,480 Da
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Fig. 3-8 Coomassie stained Tris-tricine SDS-PAGE for polypeptides gel showing 6xHistagged kisspeptin-54 purified under native conditions on a 5ml Ni-NTA column. In this
figure FT stands for flow-through fraction, WF for the wash fractions, and EF for the
elution fractions. The purity of kisspeptin-54 (Kp-54) in the 3rd elution fraction was
estimated to be 4%.

We started loading the 5ml Ni-NTA columns multiple times to increase the
amount of kisspeptin binding to the column. Increasing the concentration of imidazole in
a step-wise manner as well as a gradient optimized the imidazole concentration in the
wash. We achieved approximately 80% purity with this combination of multiple column
loading and the gradient wash (data not shown).
Since the final process of making the functional kisspeptin-54, C-terminal
amidation, is a denaturing process done in a buffer with 6M urea and 0.1M acetic acid,
we decided to add 6M urea to the lysis and elution buffers. Keeping the parameters of
multiple column-loading and gradient washes the same, the denaturing purification
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process increased the purity of the kisspeptins in the elution fractions to 90% (Fig. 3-9).
Table 3-2 lists the changes in the affinity purification protocol and the corresponding
increase in kisspeptin-54 purity. The denaturing purification protocol also increased the
yield of kisspeptin-54 by 10-fold.

Table 3-2 Purity of kisspeptin purified on the Ni-NTA columns
FPLC method

Approx. purity (%)

FPLC method with 20mM Imidazole wash (native purification)

4

EF4

EF3

EF2

EF1

WF3

WF2

WF1

FT

CL

FPLC with multiple loading of the cell lysates followed by gradient 80
wash (native purification)
FPLC with multiple loading of the cell lysates followed by gradient 90
wash (denaturing purification)
The purity was calculated by measuring the area under the kisspeptin peaks in the SDSPAGE using ImageJ.

32,300 Da
24,950 Da
14,090 Da
7,681 Da
3,480 Da

Kp-54

Fig. 3-9 Coomassie stained Tris-tricine SDS-PAGE for polypeptides gel showing 6xHistagged kisspeptin-54 purified under denaturing conditions on a 5ml Ni-NTA column. In
this figure CL stands for cell lysate, FT for flow-through fraction, WF for the wash
fractions, and EF for the elution fractions. The purity of kisspeptin-54 (Kp-54) in the 4th
elution fraction was estimated to be 90%.
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Kisspeptin purification on a reversed-phase FPLC column
To further purify kisspeptin-54 the elution fractions from the Ni-NTA purification
were loaded onto 3ml mixed-bed resin reversed phase (RP) column connected to a fast
protein liquid chromatography (RP-FPLC) system (Fig. 3-10).
The fractions were vacuum dried in a Speed-Vac and analyzed on a Tris-tricine
SDS-PAGE for polypeptides gel (Fig. 3-11). The kisspeptins were observed in the
absorbance peak fractions collected during the 10-50% acetonitrile + 0.1% trifluoroacetic
acid (TFA) gradient flow. Larger molecular weight peptides, which were not present in
the Ni-NTA elution fractions, appear in the SDS-PAGE gels.
Mid-scale expression of the kisspeptin-54 in a 20L bioreactor
To increase the amount of cell lysate available for kisspeptin purification and
amidation, we scaled-up the growth of the E. coli expressing kisspeptins to a 20L
bioreactor (Fig. 3-12). We changed to an auto-inducing high growth ZY media [51] in the
20L bioreactor to increase the bacterial density prior to induction. The post-inoculation
OD600 was 0.051. After 4h of growth the OD600 rose to 13.80 and the culture was induced
by pumping in lactose. The cells were harvested after another hour of growth at an OD600
of 15.085. The partial pressure of oxygen (pO2) was not controlled during this
fermentation. Wet bacterial cell paste (701.3g) was obtained from the mid-scale
fermentation.

ml/minute

Peaks showing
kisspeptin-54
10 – 50%
acetonitrile
+ 0.1% TFA
gradient

Absorbance at
215nm

Volume
Fig. 3-10 Purification of the kisspeptin-54 on the mixed-bed resin reverse-phase FPLC. The kisspeptins were seen in the fractions
eluted in the 215nm absorption peaks seen during the 10-50% acetonitrile + 0.1% trifluoroacetic acid (TFA) gradient wash.
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Fig. 3-11. 6xHis tagged kisspeptin-54 purified on RP-FPLC mixed-bed resin column.
Kisspeptins are seen in the fractions corresponding to the 215nm absorbance peaks. In the
figure Kp stands for kisspeptin, and EF for elution fractions.

Time
Fig. 3-12. Bio-reactor parameters for the growth of E. coli containing the kisspeptin-54 in
a 20L culture. In the figure pO2 represents the amount of oxygen pumped into the ZY
media (100µg/ml ampicillin) media. The post-inoculation OD600 of the culture was 0.051
and cells were harvested at an OD600 of 15.085.
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Purification of the kisspeptin-54 on 100 ml Ni-NTA and RP-FPLC columns
The cell paste from the 20L fermenter was lysed, centrifuged and the supernatant
loaded onto a freshly packed 100ml Ni-NTA column. The FPLC instrument was
programmed to automatically inject the cell lysate three times from the top and three
times from the bottom. This method, known as multiple column injection, exposes more
of the unbound nickel matrices to the polyhistidine tags on the kisspeptin. Though the
column wash using imidazole gradient produced 90% purity in previous runs we found
that a step-wise wash purified larger quantities of the kisspeptins. Following the wash
steps 250mM imidazole was used to elute the bound kisspeptin-54. Figures 3-13 and 3-14
shows the Ni-NTA FPLC run and the Tris-tricine SDS-PAGE for polypeptides analysis
of the elution fractions respectively.
The elution fractions with larger concentrations of the kisspeptins were pooled
and loaded onto the RP-FPLC column on the Äkta programmed for multiple injections of
the sample (Fig. 3-15). The fractions corresponding to the absorbance peaks during the
RP-FPLC were collected, lyophilized and analyzed on the Tris-tricine SDS-PAGE for
polypeptides gels. The RP-FPLC helped remove the higher molecular weight
contaminants seen in the Ni-NTA elution. However, in addition to the monomeric
kisspeptin-54, there were peptides that had molecular weights as multiples of the
kisspeptin monomer. These peptides were not present in significant amounts in the NiNTA elution fractions (Fig. 3-16). This made us wonder if the cysteine that we added to
the construct for C-terminal amidation is forming disulfide bonds with other kisspeptins.
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Volume
Fig. 3-13 Absorbance at 280nm showing the protein peaks during the sample loading, wash, and elution cycle of the FPLC. The
wash for this FPLC was done with buffer containing a mixture of 90% 5mM imidazole and 10% 250mM imidazole followed by a
mixture of 82% 5mM imidazole and 18% 250mM imidazole and the elution was performed using 250mM imidazole. In the figure
Kp-54 stands for kisspeptin-54.
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Fig. 3-14 6xHis tagged kisspeptin-54 purified on 100ml Ni-NTA column. The kisspeptins
were washed with 10% and 18% of 250mM imidazole and eluted with 100% 250mM
Imidazole. (A) SDS-PAGE analysis of the cell lysate, flow through and the first 9 elution
fractions. In the figure, 1 stands for cell lysates, 2 for flow-through, 3 – 9 for elution
fractions, Kp-54 for kisspeptin-54. (B) SDS-PAGE analysis of the cell lysate, flow
through and the next 9 elution fractions. In the figure, lanes 10 – 18 are the elution
fractions and Kp-54 for kisspeptin-54.
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Fig. 3-15 Absorbance at 280nm showing the protein peaks during the RP-FPLC. The column was washed with 0-30%
acetonitrile (+ 1% TFA) gradient for 1 column volume, held at 30% for 4 column volumes and then washed again with a 30100% acetonitrile gradient for 1 column volume and held at 100% acetonitrile for 2 column volumes. This figure shows two
successive runs. In the figure Kp-54 stands for kisspeptin-54.
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Fig. 3-16 Purification of the kisspeptins on the RP-FPLC mixed bed-resin column. Along
with the kisspeptins (molecular weight 9.7 kilodaltons), another set of peptides with an
approximate molecular weight of 20 kilodaltons is seen in the elution fractions resolved
on the Tris-tricine SDS-PAGE for polypeptides gel. In the figure, EF stands for elution
fractions and Kp-54 for kisspeptin-54.

To reduce the possibility of disulfide bond formation between kisspeptins, βmercaptoethanol was added at a ratio of 1:5 β-mercaptoethanol to kisspeptin solution.
This mixture was then incubated in 80°C water bath for 30min. However, no change in
the concentration of the suspected kisspeptin multimers was observed in the Tris-tricine
SDS-PAGE for polypeptides (Fig. 3-17).
The lyophilized kisspeptins from the RP-FPLC elution fraction were then
dissolved in the buffer for the C-terminal amidation. The amidation buffer consists of 6M
urea and 0.1M acetic acid. β-mercaptoethanol treatment was applied to the elution
fraction in the amidation buffer and the treated mixture was analyzed on the Tris-tricine
SDS-PAGE for polypeptides.
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Fig. 3-17 Treatment of the RP-FPLC elution fraction with β-mercaptoethanol. In the
figure Kp stands for kisspeptins, – and + represents the presence or absence of the βmercaptoethanol (β-ME). No reduction in the possible kisspeptin multimers was seen
after β-mercaptoethanol treatment.

The larger molecular weight peptides disappeared when the lyophilized elution
fraction in the amidation buffer was used with or without β-mercaptoethanol treatment
(Fig. 3-18). The purity of the kisspeptin-54 in the elution fraction not treated with βmercaptoethanol was determined by ImageJ software to be 91.43%. This is the highest
purity of kisspeptin-54 we obtained with our chromatography procedures.
C-terminal amidation of the kisspeptin-54
The lyophilized RP-FPLC elution fractions were dissolved in amidation buffer
consisting of 6M urea and 0.1M acetic acid and treated with 5mM CDAP for 20min as
described previously (Fig. 3-19). After hydrolysis of the resultant cyanylated protein, the
kisspeptin-54 sample was loaded onto the UPLC system equipped with a reversed phase
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C18 column. Absorbance at 270nm showed that there was no significant peak shift after
amidation, indicating that amidation was incomplete (Fig. 3-20).
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Fig. 3-18 Treatment of the RP-FPLC elution fraction with the β-mercaptoethanol in
denaturing buffer. In the figure – and + represents the presence or absence of the βmercaptoethanol (β-ME) in the denaturing buffer. The purity of kisspeptin-54 in the lane
for elution fraction without β-mercaptoethanol was calculated by ImageJ to be 91.43%

As the amidation reaction is done in an aqueous solution, we wondered if we
needed to increase the concentration of the CDAP and the reaction time to obtain a
complete amidation. The concentration of CDAP was increased to 15mM and the
reaction time was lengthened to 90 minutes. The treatment was repeated twice before
hydrolyzing the cyanylated kisspeptins with ammonia and the sample loaded onto the
UPLC. A definite peak shift was observed in the post-amidation sample as shown in Fig.
3-21 after increasing the CDAP concentration and reaction time. The amidated kisspeptin
was then buffer exchanged into PBS using a 2000 dalton molecular weight cut off
membrane and stored in -80°C for use in biological assays. A small amount of amidated
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kisspeptin solution was buffer exchanged with 50mM ammonium bicarbonate,
lyophilized and sent to Alphalyze for mass-spectroscopic evaluation of the peptide.

Fig. 3-19 C-terminal amidation reaction pathway of the kisspeptin-54. CDAP cyanylates
the cysteine in the kisspeptin-54 construct and the ammonia cleaves the amidated
kisspeptin from the iminothiazolidine-peptide.
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Fig. 3-20. Absorbance at 270nm peaks of the kisspeptins before and after amidation. No
peak shift after amidation is observed. The UPLC analysis was performed by Justin
Jones.
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Time
Fig. 3-21. Absorbance at 270nm peaks of the kisspeptins before and after multiple
amidations. Definite peak shift after amidation is seen. The UPLC analysis was
performed by Justin Jones.

The amidated kisspeptin-54 is seen as a peak with the molecular weight of
7677.59 daltons in the mass-spectroscopy results. This is close to the calculated
molecular weight of 7887g/mol for the amidated kisspeptin-54. The expected mass of the

49
complete kisspeptin-54 peptide is 9664.94 g/mol. The mass spectroscopy data shown in
Fig. 3-22, is the final confirmation of the C-terminal amidation of the kisspeptins. The
peptide controls used for the mass-spectroscopy are listed in Appendix D.

Kp-54-NH2

Fig. 3-22. C-terminal amidated kisspeptins (molecular weight 7887 daltons) identified
using the mass spectrometry. The top panel shows peaks corresponding to 700-3500
dalton peptides used as controls. The second panel from the top shows the peaks of the
700-3500 dalton peptides present in the kisspeptin-54 sample. The third panel from the
top shows peaks corresponding to 3500-15000 dalton peptides used as controls. The
bottom panel shows the peaks of the 3500-15000 dalton peptides present in the
kisspeptin-54 sample.
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Biological assays of kisspeptin-54 activity
A previous study described the effect of kisspeptin-54 on intracellular calcium
mobilization in Chinese hamster ovary cells expressing the kisspeptin receptor, GPR54
[28]. Chemically produced kisspeptin-10 was shown to increase phosphorylation of the
Erk1/2 proteins in these cells [20]. In a search of PubMed, we were unable to find any
publications where kisspeptin-54 was shown to phosphorylate Erk1/2 proteins in CHO-G
cells. Given that our focus was on developing a method that uses relatively inexpensive
instrumentation, is easier to perform, and can be replicated in most laboratories doing
biological or chemical work, we decided to test Erk1/2 phosphorylation as a possible
readout for our biological assay.
Effect of unamidated kisspeptins on Erk1/2 activation
The C-terminal amidation of kisspeptins has been reported to play a role in the
activation of the GPR54 receptor [20, 28]. Unamidated kisspeptins were found to be less
potent than the amidated ones [28]. Unpublished work done by the Welch group
indicated that the unamidated kisspeptins might have effects on heterologous cell
expression systems (Danny Welch, University of Kansas). In an exploratory assay, we
measured Erk1/2 phosphorylation after treating CHO-G and CHO-0 cells with
unamidated kisspeptin-54.
CHO-G and CHO-0 cells were grown and treated with unamidated kisspeptin-54
as described in chapter 2. Phosphorylated Erk1/2 proteins were visualized on X-ray film
(Fig. 3-23). The raw signal intensity, which is proportional to the quantity of
phosphorylated Erk1/2, was measured using a Gel Doc EZ System (Bio-Rad Hercules,
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CA). Since the molecular weights of the phosphorylated Erk1/2 proteins (44 and 42
kilodaltons) is close to the β–actin loading control (54 kilodaltons), histone H3 (17
kilodaltons) was substituted as the loading control. Unfortunately, histone H3 is
expressed in higher levels in treated CHO-0 cells compared to treated CHO-G cells.
Therefore, concurrent SDS-PAGE gels, stained with Coomassie were run to demonstrate
the consistency of protein loading. SDS-PAGE gels were loaded with exactly the same
amount of cell lysates by weight, as determined by BCA, for the immunoblots. Nine
samples from 3 replicate plates for both CHO-G and CHO-0 were analyzed using
immunoblots. Fig 3-24 shows that the unamidated kisspeptins have activity similar to the
chemically synthesized kisspeptins in increasing phosphorylation of Erk1/2 in CHO cells
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Fig. 3-23 Phosphorylation of Erk1/2 after stimulation of CHO-G and CHO-0 cells with
1µM unamidated kisspeptin-54. Immunoblots were done with anti-phospho-Erk1/2
antibodies. Both the CHO-0 and CHO-G cells exhibit phosphorylation of Erk1/2.
However, phosphorylation is substantially higher in CHO-G cells. Nine samples from 3
replicate plates for both CHO-G and CHO-0 were loaded.

Area
(Intensity)

52

CHO-G

CHO-0

Fig. 3-24. Phosphorylation of Erk1/2 after stimulation of CHO-G and CHO-0 cells with
1µM unamidated kisspeptin-54. The area of the signal is measured as intensity (unit
defined by Bio-Rad Hercules, CA). Nine samples from 3 replicate plates for both CHO-G
and CHO-0 were loaded. Error bars represent standard deviation.

Effect of amidated kisspeptins on Erk1/2 activation
CHO-G and CHO-0 cells were treated with 1µM kisspeptin-54 for both
biologically and chemically derived forms as described previously. Eleven samples from
4 replicate plates for both CHO-G and CHO-0 cells were treated with biologically
synthesized kisspeptin-54. Three samples from 1 plate for both CHO-G and CHO-0 cells
were treated with chemically synthesized kisspeptin-54. The signal intensity of the
phosphorylated Erk1/2 was quantified using a Gel Doc EZ System (Bio-Rad Hercules,
CA) (Fig. 3-25 and 3-26 show two separate experiments). SDS-PAGE gels stained with
Coomassie were used as loading controls. Fig. 3-27 shows that the biologically
synthesized and amidated kisspeptins behave similarly to the chemically synthesized
amidated kisspeptins in increasing phosphorylation of the Erk1/2 in CHO-G cells.
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p-Erk1/2
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Fig. 3-25 Phosphorylation of Erk1/2 after stimulation of CHO-G and CHO-0 cells with
1µM amidated kisspeptin-54. Immunoblots were done with anti-phospho-Erk1/2
antibodies. Lanes 1, 2, 3, 4, 5, 6, 7, and 8 were loaded with cells treated with amidated
kisspeptin-54 produced in E. coli. Lanes 9 and 10 were loaded with cells treated with
amidated kisspeptin-54 produced by chemical means at Phoenix Pharmaceuticals. Lanes
2, 4, 6, 8, and 10 were loaded with CHO-G cells. Lanes 1, 3, 5, 7, and 9 were loaded with
CHO-0 cells.

p-Erk1/2
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Fig. 3-26 Phosphorylation of Erk1/2 after stimulation of CHO-G and CHO-0 cells with
1µM amidated kisspeptin-54. Immunoblots were done with anti-phospho-Erk1/2
antibodies. Lanes 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, and 15 were loaded with cells
treated with amidated kisspeptin-54 produced in E. coli. Lanes 9, 16, 17, and 18 were
loaded with cells treated with amidated kisspeptin-54 produced by chemical means at
Phoenix Pharmaceuticals. Lanes 2, 3, 5, 7, 9, 10, 12, 14, and 17 were loaded with CHO-G
cells. Lanes 1, 4, 6, 8, 11, 13, 15, 16, and 18 were loaded with CHO-0 cells.
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Fig. 3-27 Phosphorylation of Erk1/2 after stimulation of CHO-G and CHO-0 cells with
1µM amidated kisspeptin-54. The area of the signal is measured as intensity (unit defined
by Bio-Rad Hercules, CA). Eleven samples from 4 replicate plates for both CHO-G and
CHO-0 cells were treated with biologically synthesized kisspeptin-54. Three samples
from 1 plate for both CHO-G and CHO-0 cells were treated with chemically synthesized
kisspeptin-54. Error bars represent standard deviation.

Effect of amidated kisspeptins on Akt1/2 activation
We examined the possibility that amidated kisspeptin-54 would phosphorylate
Akt. We reduced the concentration of the amidated kisspeptin-54 from 1µM to 0.25µM to
reduce any non-specific responses. Six samples from 4 replicate plates for both CHO-G
and CHO-0 cells were treated with biologically synthesized kisspeptin-54. Three samples
from 1 plate for both CHO-G and CHO-0 cells were treated with chemically synthesized
kisspeptin-54. Kisspeptins are not known to activate Akt in CHO cells transfected with
GP54 [52]. We found that Akt was phosphorylated after treatment with both biologically
and chemically synthesized amidated kisspeptins (Fig. 3-28, 3-29). SDS-PAGE gels
loaded with the cell lysates and stained with Coomassie were used as loading controls.
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Our results, thus, show that the kisspeptin-54 produced in transformed E. coli behaves
similarly to the kisspeptins that have been produced by chemical means (Fig. 3-30).
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Fig. 3-28 Phosphorylation of Akt after stimulation of CHO-G and CHO-0 cells with
250nM amidated kisspeptin-54. Immunoblots done with anti-phospho-Akt antibodies.
Lanes 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, and 12 were loaded with cells treated with amidated
kisspeptin-54 produced in E. coli. Lanes 13, 14, 15, 16, 17, and 18 were loaded with cells
treated with amidated kisspeptin-54 produced by chemical means at Phoenix
Pharmaceuticals. Lanes 2, 4, 6, 8, 10, 12, 14, 16, and 18 were loaded with CHO-G cells.
Lanes 1, 3, 5, 7, 9, 11, 13, 15, and 17 were loaded with CHO-0 cells.
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Fig. 3-29. Phosphorylation of Akt after stimulation of CHO-G and CHO-0 cells with
250nM amidated kisspeptin-54. The area of the signal is measured as intensity (unit
defined by Bio-Rad Hercules, CA). Six samples from 4 replicate plates for both CHO-G
and CHO-0 cells were treated with biologically synthesized kisspeptin-54. Three samples
from 1 plate for both CHO-G and CHO-0 cells were treated with chemically synthesized
kisspeptin-54. Error bars represent standard deviation.
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Fig. 3-30. Phosphorylation of Akt and Erk1/2 proteins by kisspeptin-54. The figure is a
composite of the previously described phosphorylation effects of biologically synthesized
unamidated kisspeptin-54, biologically synthesized amidated kisspeptin-54 and
chemically synthesized amidated kisspeptin-54. Visualizing all the phosphorylation
effects helps to assess the relative effects of the different types of kisspeptins on the
phosphorylation of Akt and Erk1/2 proteins in CHO-G and CHO-0 cells. The figure also
shows that the biologically and chemically synthesized amidated kisspeptins show similar
phosphorylation effect.
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CHAPTER 4
DISCUSSION
Kisspeptins are hormones with an arginine-phenylalanine motif that are present in
most human tissues and initiate puberty in adolescents, maintain sexual function in adults
and act to prevent the metastases of certain cancers [2, 14]. The role of kisspeptins in
alleviating endocrine disorders and preventing the spread of cancer makes it an attractive
therapeutic agent [2, 14]. Little is known about the mechanism of action of the
kisspeptins at a cellular level [2]. Kisspeptins synthesized by chemical or
biotechnological means can be used as reagents for research into kisspeptins mode of
action, and potentially as therapeutic agents. Our goal was to design a simple method for
the expression of kisspeptins in transformed bacterial cells and purification of the
expressed kisspeptins. Once the purified kisspeptins were obtained, they were used to
develop an assay to probe its biological actions.
The in-silico designed kisspeptin-54 construct (Figs. 2-1, 2-2), with an OmpA
secretion signal and the C-terminal 6x histidine tag, showed high level expression in
response to the IPTG induction (Fig 3-3). Previous studies have shown that secretion tags
increase protein expression [38]. The kisspeptin-54 construct with the OmpA secretion
tag showed high level expression whereas the kisspeptin-54 without the tag did not
(Table 2-1). The attached secretion signal may have aided the kisspeptin-54 high level
expression. However, no expression was seen for the 145 amino acid full-length KISS1
peptide even in the presence of the OmpA tag. We do not know if the full-length KISS1
peptide has low-expression even with a secretion tag or if it gets expressed and then is
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degraded into smaller components. The peptide expressed in high levels in the E. coli
with kisspeptin-54 construct was resolved by Tris-tricine SDS-PAGE for polypeptides
and identified using mass-spectroscopy as the recombinant kisspeptin-54 (Fig. 3-2).
The polyhistidine tag at the C-terminal end of the kisspeptin construct was
utilized in the pilot affinity purification using a bench-top Ni-NTA kit (Fig. 3-3). The
major peptide purified on the Ni-NTA column was identified as the kisspeptin-54
construct using mass-spectroscopy (Fig. 3-4).
The kisspeptin-54, that we purified, was still in a unamidated form. However,
although the C-terminal amidation of the kisspeptin-54 is required for the maximum
activation of the kisspeptin receptor - GPR54, unamidated kisspeptins also activate the
receptor and elicit responses similar to the amidated kisspeptins when used in
heterologous cell expression systems (Danny Welch, University of Kansas, personal
communication). Thus we decided to investigate the effect of the bench-top purified
unamidated kisspeptin-54 on cell proliferation. We chose cell proliferation as our readout
because the amidated kisspeptin-10 down-regulates cell proliferation in cells expressing
GPR54. We treated the CHO-G and CHO-0 cells with unamidated kisspeptin-54
expressed and purified in our lab and compared these treated cells to cells treated with
chemically synthesized and amidated kisspeptin-54 and kisspeptin-10 purchased from
Phoenix Pharmaceuticals. We found that unamidated bacterially produced kisspeptin-54
behaved similarly to the chemically synthesized kisspeptin-54 and kisspeptin-10 in
reducing the proliferation of the CHO-G cells relative to the CHO-0 cells (Fig. 3-5).
Based on the biological activity displayed by the unamidated kisspeptin-54
produced in the lab we decided to grow 2L volumes of the E. coli strain with the
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kisspeptin-54 constructs using a high-density bench-top fermenter (Fig. 3-6). After
approximately 5h post-IPTG induction and a cell-density (OD600) between 3 and 4, we
noticed that the LB-carbenicillin media started foaming, probably from the lysis of the E.
coli. We are not sure if the lysis was caused from the E. coli reaching a certain population
density or the expression of kisspeptins-54 becoming toxic to the E. coli. In any case this
prevented a higher level of bacterial growth after inducing.
The initial purification on the 5ml Ni-NTA columns used buffers containing the
imidazole and no urea, as we wanted to use buffers that would help preserve the native
conformation of the kisspeptins (Fig. 3-7). This purification did not remove most of the
impurities and the kisspeptin-54 purity in the elution fractions was estimated using SDSPAGE and ImageJ to be only 4% (Fig. 3-8). To increase the purity of the kisspeptin yield
we reduced the imidazole concentration in the lysis buffer to encourage more kisspeptin
to bind to the column. We then optimized the imidazole concentration in the wash buffer
by using various imidazole concentrations in a step-wise manner as well as a gradient.
We also repeatedly loaded the column with the same cell lysate to increase the exposure
of the kisspeptin-54 and the Ni-NTA column. This repeated column binding from both
the ends of the column and an imidazole gradient helped us obtain kisspeptins with
approximately 80% purity.
Since it was clear that a substantial fraction of the expressed protein was insoluble
in the initial extraction buffer, we decided to switch to the denaturing buffers containing
urea for the purification as urea decreases hydrophobic interactions between and within
insoluble peptides thereby increasing its solubility [54]. Since the buffer for performing
the amidation contains 6M urea and will denature any kisspeptin-54, we felt comfortable
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in using urea in all steps of the nickel affinity purification. We also reduced the
concentration of urea from 8M to 6M to match the urea concentration in the amidation
buffer. Use of denaturing buffer with urea increased our kisspeptin purity to
approximately 90% (Fig. 3-9).
Once we were comfortable with our expression and purification methodology and
responsiveness of the CHO-G cells to the kisspeptins, we scaled up the expression and
purification to obtain sufficient quantities of the kisspeptins for amidation and biological
testing. For scale-up we chose to use an auto-induction ZY media [51] in a 20L fermenter
(Fig. 3-12). Instead of using expensive IPTG to induce the kisspeptin-54 expression, the
cheaper lactose was pumped in for auto-induction after the cells attained a set density.
We had noted previously that these cells after a certain length of time start lysing in the
fermenter. Cell lysis was also observed in pilot ZY media runs after approximately 1 hour
post-induction but the OD600 was usually above 12. We, therefore, hypothesized that the
kisspeptin-54 expression plays a role in the cell lysis. Therefore, the 20L ZY medium
culture was inoculated with the E. coli carrying the kisspeptin-54 constructs and grown
for 4h till its OD600 reached 13.8 when lactose was pumped in to induce the kisspeptin-54
expression. The cells were harvested an hour later and the final OD600 was 15. The 20L
fermentation provided us with 701.3g of wet bacterial cell paste. The ZY media thus
helped us to grow E. coli to high density to increase the kisspeptin yield and at the same
time avoid the lysis of the E. coli expressing the kisspeptin-54.
The affinity purification of the kisspeptin-54 in the E. coli cell paste from the 20L
fermentation was performed using a 100ml Ni-NTA column (Fig. 3-13). While
optimizing the 5ml Ni-NTA purification we had found that maximal protein purification
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we achieved by washing the column with an increasing concentration of imidazole. This
methodology removes the least binding impurities first followed by peptides that bind
more tightly.
By applying the changes to the purification protocol discussed above – multiple
column loading and use of urea, the amount of kisspeptin-54 obtained after the
purification was approximately 10-fold higher from the 100ml Ni-NTA column
purification. This run provided us with the largest amount of kisspeptin-54 as visualized
on the Tris-tricine SDS-PAGE for polypeptides gels (Fig. 3-14). The gels also showed
persistent high molecular weight contaminants in all the elution fractions analyzed. In the
elution fractions with higher concentrations of the kisspeptins we see the appearance of
peptides with double the molecular weight of the kisspeptin-54. These possible multimers
were not seen in purifications producing lesser amount of kisspeptins since their levels
were not high enough to detect. To purify the kisspeptins even further we tried size
exclusion chromatography and a mixed-bed resin reverse-phase column connected to the
FPLC machine. The size exclusion chromatography did not work due to difficulties with
column packing and loading so instead we focused on improving purification using the
reverse-phase (RP) column.
The 100ml Ni-NTA elution fractions were further purified using an RP column
connected to the FPLC (Fig. 3-15). But along with the kisspeptins, peptides with double
the molecular weight of kisspeptin-54 were apparent in the Tris-tricine SDS-PAGE for
polypeptides gels (Fig. 3-16). Since the higher molecular weight peptides, probably
kisspeptin-54 multimers, were not seen in significant amounts in most of the Ni-NTA
elution fractions we hypothesized that the higher kisspeptin-54 peptide concentration in
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the RP-FPLC elution fractions may be aggregating the kisspeptin-54 by disulfide bond
formation or some other intermolecular interactions. Since cysteine, which can form
disulfide links with other cysteines, was added to the amino acid chain of the kisspeptin
construct for C-terminal amidation we wondered if the aggregates could be resolved into
monomeric form by treating them with thiols.
The multimers, on treatment with β-mercaptoethanol, did not resolve into
peptides with molecular weights similar to the kisspeptins (Fig. 3-17). However, on
treating the RP-FPLC elution fraction with 6M urea in 0.1M acetic acid the multimers
resolved into kisspeptin monomers as visualized using the Tris-tricine SDS-PAGE for
polypeptides gels (Fig. 3-18). To summarize, the Ni-NTA purification helped us obtain
kisspeptin-54 of high purity and the RP-FPLC helped us remove the high molecular
weight contaminants. The kisspeptins aggregates in the RP-FPLC fractions were reduced
to the monomeric form. The final purity of the kisspeptins monomers estimated by the
ImageJ software was 91.4%.
The C-terminal amidation, performed using the cyanylating agent CDAP [27, 39],
converted the unamidated kisspeptins to C-terminal amidated kisspeptins (Fig. 3-19).
When we first tried the C-terminal amidation, the amidation was incomplete as seen after
analyzing the sample on a UPLC (Fig. 3-20). Since the cyanylation reaction is happening
in an unfavorable aqueous media, we decided to increase the concentration of the
cyanylating reagent, prolong the reaction, and then repeat the amidation reagent addition
two more times. Changes in the C-terminal amidation reaction parameters were reflected
as a clear peak shift in the UPLC indicating a successful and completed amidation (Fig.
3-21).
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The amidated kisspeptin was sent for mass-spectroscopic evaluation. The massspectroscopic readout showed a peak of molecular weight 7678 close to 7887g/mol
molecular weight of the C-terminally amidated kisspeptin-54 (Fig. 3-22). The mass
difference is likely due to inaccurate calibration of the mass spectrometer with different
possible counter ions bound to our peptide. The mass of the unamidated kisspeptin-54 is
9664.94g/mol and thus the only result of this reaction to reduce the mass is cleavage and
formation of the C-terminal amide.
We found that unamidated kisspeptins down regulated CHO-G cell proliferation.
For a better biological assay for our kisspeptin-54, we used the effect of kisspeptin-54 on
phosphorylation of Erk1/2 and Akt proteins. Previous work on the phosphorylation of
Erk1/2 and Akt in CHO cells utilized kisspeptin-10 rather than the kisspeptin-54 [20, 52].
Both Erk1/2 and Akt are involved in cell proliferation. Activation of GPR54 by
kisspeptins sets up a signaling cascade resulting in the activation of PKC and the release
of intracellular calcium to bring about the phosphorylation of Erk1/2 (Fig. 4-1). The
intermediary players in the phosphorylation of Akt by the kisspeptins are not known.
Although the cell signaling effects of kisspeptin depends on cell type, Erk1/2
phosphorylation has been seen in CHO-G and other cells expressing the GPR54 [2].
Though the plasma kisspeptin levels in adult males and non-pregnant adult females are
less than 2pmol/L [55], we used a 1µM concentration of our kisspeptin-54 for the
treatment since maximal phosphorylation of the Erk1/2 was seen with the application of
1µM kisspeptin-54 on papillary thyroid cancer cells [36]. Since no Akt phosphorylation
was expected after the kisspeptin treatment we lowered the kisspeptin-54 concentration to
suppress any non-specific activation of kinases involved in the Akt phosphorylation.
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We treated CHO-G and CHO-0 cells with unamidated biologically synthesized
kisspeptin-54, amidated biologically synthesized kisspeptin-54 and chemically
synthesized amidated kisspeptin-54. All three of these treatments increased the
phosphorylation of Erk1/2 in CHO-G cells to a much higher extent than for the CHO-0
cells (Figs. 3-23, 3-24, 3-25, 3-26, 3-27, 3-30). The Akt experiments were performed
with the amidated biologically synthesized kisspeptin-54 and chemically synthesized
amidated kisspeptin-54. Although a previous study [52] did not find any evidence of Akt
phosphorylation after kisspeptin-10 treatment of CHO cells expressing the GPR54, we
found that both amidated biologically synthesized and chemically synthesized amidated
kisspeptin-54 led to the phosphorylation of Akt (Fig. 3-28, 3-29, 3-30). However in
agreement with this finding, kisspeptin-54 treatment of papillary thyroid carcinoma
resulted in increased phosphorylation of Erk1/2 and Akt [56]. The conformational change
brought about by kisspeptin-54 binding to the GPR54 receptor in the CHO cells may
recruit and activate the phosphoinositide-3-kinase (PI3K) enzyme resulting in the
phosphorylation of Akt. The kisspeptin-10 may not bring about this conformational
change in GPR54 thereby not leading to the phosphorylation of Akt. The phosphorylation
of Akt by our kisspeptin-54 may be due to possible cell signaling mechanisms still
undiscovered [10]. However, the differential Akt phosphorylation response in the cells
with the receptor compared to the control cells without the kisspeptin receptor alludes to
a receptor-mediated effect. Based on the biological assays we demonstrated that the
biologically synthesized kisspeptins behave similar to the chemically synthesized
kisspeptins.
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Fig. 4-1 Erk1/2 and Akt phosphorylation by kisspeptin-54. Erk1/2 is activated by PKC
and intracellular calcium. The mechanism underlying the phosphorylation of Akt in CHO
cells by kisspeptin-54 is not known.
This work has led to a simpler way to express and purify kisspeptin-54 for use as
a research or therapeutic reagent. Table 4-1 compares a published method used by
another research group with the methodology used in our study [27]. The current
investigation has also developed a simple immunoblot method to validate kisspeptin-54
for biological use. The biologically produced kisspeptin-54 will allow investigations of
the biochemical and cellular underpinnings of kisspeptin-54’s physiological effects.
We estimated the cost of the production of kisspeptin-54 in bacterial systems. The
total cost to produce 9000µg of the amidated kisspeptin-54 expressed in E. coli from 20L
fermentation is $1192.36. Therefore, to produce 100µg of the amidated kisspeptin-54 in
our bacterial system is $13.24. The purchase price of 100µg of the amidated kisspeptin54 produced by chemical means is $235.00 (Phoenix Pharmaceuticals, Burlingame, CA
Catalog # 048-59). Our kisspeptin-54 is thus approximately 17 times less expensive than
kisspeptin-54 produced by chemical methods. The cost estimate is detailed in Appendix
E.
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Table 4-1 Comparison of kisspeptin purification done in the Lewis Lab and by Takeda
Chemical Industries
Purification Method (Takeda Chemical
Purification Method (Lewis Lab)
Industries)
Purification of the kisspeptins on heparinPurification of the kisspeptins on histidineaffinity column
affinity column
Cyanylation
Purification on the size exclusion column
Hydrolysis of the cyanylated kisspeptin

Purification on a reverse-phase column
Amidation
Amidated kisspeptin buffer exchange to
PBS

Purification on the size exclusion column
Purification on an ion exchange column
Purification on a reverse-phase column

In conclusion, we designed a kisspeptin-54 construct and successfully used it to
expressed kisspeptin-54 in E. coli. Kisspeptin-54 was purified by Ni-NTA
chromatography to approximately 90% purity. Further purification of the kisspeptin-54
was done on RP-FPLC columns to 91.4% purity. The purified kisspeptins were amidated
at the C-terminal of the peptide using a cyanylation reagent and then buffer exchanged
into PBS for biological assays. CHO-G and CHO-0 cells were treated with the
biologically synthesized amidated kisspeptins and their responses were compared with
responses to chemically synthesized amidated kisspeptins. The biologically and
chemically synthesized amidated kisspeptins activated Erk1/2 and Akt phosphorylation in
CHO-G cells. Phosphorylation of Erk1/2 and Akt signaling is associated with cell
proliferation in cancer metastasis. Thus, our biologically synthesized amidated
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kisspeptins produced the same change in cellular signaling as chemically synthesized
amidated kisspeptins.
To summarize, our work with kisspeptins has led to the following results:
•

Produced up to 450µg of kisspeptin-54 per liter from the E. coli
fermentation. The cost of producing our kisspeptin-54 is17 times less than
the price of the chemically synthesized kisspeptins.

•

Designed a successful amidation process

•

Demonstrated that the peptide has the same biological effect as the
synthetic version
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APPENDIX A
KISSPEPTIN-54 PLASMID SYNTHESIZED BY DNA 2.0

Fig. A-1 Plasmid map of the kisspeptin-54 construct. The kisspeptin-54 (DNA 2.0 Gene
ID: 30726) construct is inserted in the pJExpress404 vector (DNA 2.0). The plasmid map
also shows the T5 promoter, the ampicillin resistance gene and the restriction sites.
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APPENDIX B
MASS SPECTROSCOPIC IDENTIFICATION OF KISSPEPTIN-54 EXPRESSION

Fig. B-1 Mass-spectroscopy data confirming the high level expression of kisspeptin-54 in
E. coli. Fragments of kisspeptins from the highly expressed band in the gel (Fig. 3-1)
covered 60% of the amino acids sequences expected to be synthesized by the kisspeptin54 construct. These fragments are shown to be matching perfectly with the recombinant
kisspeptin-54 expected to be produced in the transformed E. coli.
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APPENDIX C
MASS SPECTROSCOPIC IDENTIFICATION OF KISSPEPTIN-54 PURIFICATION
USING NI-NTA AFFINITY CHROMATOGRAPHY

Fig. C-1 Mass-spectroscopy data confirming the presence of kisspeptin-54 in the 1st
elution fraction from Ni-NTA chromatography. Fragments of kisspeptins from the 1st
elution fraction band corresponding to the molecular weight of the recombinant
kisspeptin -54 in the SDS-PAGE gel (Fig. 3-3) covered 31% of the amino acids
sequences expected to be synthesized by the kisspeptin-54 construct.
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Fig. C-2 Mass-spectroscopy data confirming the presence of kisspeptin-54 in the 2nd
elution fraction from Ni-NTA chromatography. Fragments of kisspeptins from the 2nd
elution fraction band corresponding to the molecular weight of the recombinant
kisspeptin -54 in the SDS-PAGE gel (Fig. 3-3) covered 60% of the amino acids
sequences expected to be synthesized by the kisspeptin-54 construct.
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APPENDIX D
PEPTIDE CONTROLS USED IN THE CONFIRMATION OF KISSPEPTIN-54
AMIDATION BY MASS SPECTROSCOPY

Fig. D-1 The peptide controls used as protein calibration standards in the confirmation of
kisspeptin-54 amidation by mass spectroscopy.
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APPENDIX E
COST OF PRODUCING BACTERIAL KISSPEPTIN-54
Total cost to produce 9000µg of the amidated kisspeptin-54 expressed in E. coli from 20liter fermentation is $1192.36
To produce 100µg of the kisspeptin-54 expressed in E. coli is $13.24
The cost of 100µg chemically synthesized kisspeptin-54 (product ID: 048-59) purchased
from Phoenix Peptides is $235.00
Table E-1 Cost of reagents for the 20L fermentation
Chemicals
Manufacturer Code
Size
NZ-Amine A Amresco
J853-1KG
1KG
Yeast Extract Amresco
J850-10KG 10KG
Dextrose
Amresco
0188-50KG 50KG
Lactose
Amresco
J815-12KG 12KG
Ammonium Amresco
0191-50KG 50KG
Sulfate
Potassium
Amresco
0781-50KG 50KG
Phosphate
Sodium
Amresco
0404100KG
Phosphate
100KG
Magnesium
Alfa Aesar
A14491
5KG
Sulfate
Ampicillin
Amresco
0339-100G 100G
Trace
---Minerals
Total

Price
$127.95
$673.64
$497.44
$298.39
$574.87

Price per run
$25.59
$6.74
$0.44
$0.99
$0.76

$954.27

$2.60

$1236.53

$1.76

$90.60

$0.18

$244.27
--

$4.89
$0.26
$44.21
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Table E-2 Cost of reagents for trace mineral stock solution
Trace
Manufacturer Product
Size
Mineral
Number
Iron (III)
Alfa Aesar
12357
25KG
chloride
Calcium
Alfa Aesar
L13191
5KG
chloride
Manganese
Alfa Aesar
11868
10KG
(II) chloride
Zinc
Alfa Aesar
A16281
10KG
chloride
Cobalt (II)
Alfa Aesar
12303
250G
chloride
Copper (II)
Alfa Aesar
12457
1KG
chloride
Nickel (II)
Alfa Aesar
14687
500G
chloride
Sodium
Alfa Aesar
A19222
2.5KG
molybdate
Sodium
Alfa Aesar
12613
1KG
selenate
Boric acid
Alfa Aesar
A10896
10KG
Total
Table E-3 Cost of reagents for 100ml Ni-NTA FPLC
Chemicals
Manufacturer Code
Size
Nickel for
GE
17531804
2L
the Ni-NTA
column
Urea

Amresco

0378100KG
S2554-3KG

100KG

Price
$208.00

Price for
100 ml stock
$0.11

$134.00

$0.08

$227.00

$0.04

$572.00

$0.16

$175.00

$0.33

$97.50

$0.03

$290.00

$0.28

$425.00

$0.08

$355.00

$0.19

$143.00

$0.002
$1.30

Price
$12,600

Price per run
$632.00
(can be
reused >50
times =
$12.64)
$49.11

$908.15

Sodium
Sigma
3KG
$722.00
$21.66
phosphate
Aldrich
Sodium
Alfa Aesar
12314
10KG
$114.00
$3.00
Chloride
Imidazole
Alfa Aesar
A10221
2.5KG
$242.00
$8.60
Total
$95.01
3 runs of 100ml column Ni-NTA purification (with the reuse of the column) will cost
$285.03
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Table E-4 Cost of reagents for reversed-phase column purification on the FPLC
Chemicals
Manufacturer Code
Size
Price
Price per run
(each run has
6 stacked
injections)
Mixed Bed
GE
17-1182-01 3ml
$350
$3.50/run
Column (100
injections life
cycle)
Acetonitrile
Alfa Aesar
22927
4 x 4L
$667.00
$83.38
Trifluoroacetic Alfa Aesar
44630
4 x 500ml
$589.00
$2.95
acid
Total
$89.83
3 runs of reversed-phase purifications (with the reuse of the column) on the FPLC will
cost $269.49
Table E-5 Cost of reagents for C-terminal amidation
Chemicals
Manufacturer Code
Size
1-cyano-4Alfa Aesar
(dimethylamino)
pyridinium
tetrafluoroborate
Urea
Amresco

H59334

500mg

$282.00

Price per
run
$178.92

0378100KG
33252
L13168

100KG

$908.15

$0.10

$278.00
$40.50

$0.002
$0.10

Acetic acid
Alfa Aesar
20L
Ammonium
Alfa Aesar
2.5L
hydroxide
Total
3 rounds of C-terminal amidation costs $537.36

Price

$179.12

Table E-6 Cost of membranes for dialysis
Dialysis
Manufacturer Code
Size
Price
Price per run
Membrane
2K MWCO Thermo
66230
6 cassettes
$91.00
$15.17
Fisher
3 round of dialysis of the C-terminally amidated kisspeptin-54 costs $45.50
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Table E-7 Cost of reagents for PBS buffer exchange
Chemicals
Manufacturer Code
Size
Price
Price per run
Sodium
Alfa Aesar
12314
10KG
$114.00
$1.82
Chloride
Potassium
Alfa Aesar
11595
5KG
$126.00
$0.10
Chloride
Sodium
Amresco
0404100KG
$1236.53
$0.36
Phosphate
100KG
Potassium
Alfa Aesar
11594
1KG
$85.00
$0.41
Phosphate
Total
$2.69
Total cost of the PBS for the entire post-amidation buffer exchanges is $8.07
Table E-8 Cost of reagents for ammonium bicarbonate buffer exchange
Chemicals
Manufacturer Code
Size
Price
Price per run
Ammonium Alfa Aesar
14249
5KG
76.20
$0.90
bicarbonate
Total cost of the ammonium bicarbonate for the entire post-amidation buffer exchanges is
$2.70
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